1008517-68-7

Usage

Chemical Structure

Consists of a benzene ring with a hydroxyl group (-OH) and a chloroethyl group (-CH2CH2Cl) attached to it.

Application

Pharmaceutical Synthesis: Used in the synthesis of pharmaceuticals.
Industrial Production: Employed in the production of various industrial products.
Organic Compound Manufacturing: Serves as a building block in the manufacturing of other organic compounds.

Versatility

The presence of the chloroethyl group makes it valuable as a starting material for the preparation of a wide range of organic compounds.

Importance in Organic Synthesis

Acts as a versatile and important chemical in the field of organic synthesis.
Enables the creation of diverse organic compounds due to its structural properties.

Usage

Commonly utilized in pharmaceutical, industrial, and organic synthesis applications.

Key Functional Groups

Benzene Ring
Hydroxyl Group (-OH)
Chloroethyl Group (-CH2CH2Cl)

Upstream product

• 20849-78-9 p-(beta-chloroethyl)benzoic acid 

Downstream Products

• 1008517-67-6 [4-(2-iodo-ethyl)-phenyl]-methanol 
• 1008517-69-8 4-benzyloxy-1-[2-(4-hydroxymethyl-phenyl)-ethyl]-1H-pyridin-2-one 
• 1008518-50-0 4-benzyloxy-1-[2-(4-bromomethyl-phenyl)-ethyl]-1H-pyridin-2-one 
• 1444684-45-0 C₁₅H₂₅N₄⁽¹⁺⁾ 
• 864529-24-8 [4-(2-azido-ethyl)-phenyl]-methanol 
• 103076-33-1 4-β-chloroethylbenzaldehyde 
• 1008518-84-0 6-benzyloxy-3-[2-(4-hydroxymethyl-phenyl)-ethyl]-3H-pyrimidin-4-one 

Relevant academic research and scientific papers

NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS

The present invention relates to compounds of general formula (I) wherein the groups and radicals B, k, L, U,V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH- receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Novel azole compound

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes.The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.